Compass Therapeutics (NASDAQ:CMPX) Earns Buy Rating from D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX) in a research report released on Wednesday,Benzinga reports. The brokerage currently has a $32.00 price target on the stock.

Other equities research analysts have also issued reports about the company. Leerink Partnrs cut Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 15th. LADENBURG THALM/SH SH upgraded shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 target price on the stock in a report on Monday, September 16th. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Compass Therapeutics in a report on Monday, November 11th. Finally, Leerink Partners downgraded shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $5.00 to $4.00 in a research note on Friday, November 15th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Compass Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $11.80.

Compass Therapeutics Trading Down 4.8 %

Shares of CMPX opened at $1.77 on Wednesday. The firm has a fifty day moving average price of $1.57 and a 200-day moving average price of $1.45. The firm has a market capitalization of $243.53 million, a P/E ratio of -4.78 and a beta of 0.92. Compass Therapeutics has a 12-month low of $0.77 and a 12-month high of $2.68.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.03. Analysts predict that Compass Therapeutics will post -0.35 earnings per share for the current year.

Hedge Funds Weigh In On Compass Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of CMPX. Geode Capital Management LLC boosted its position in shares of Compass Therapeutics by 0.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock worth $4,251,000 after purchasing an additional 19,095 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Compass Therapeutics by 12.4% in the second quarter. Bank of New York Mellon Corp now owns 283,938 shares of the company’s stock valued at $284,000 after buying an additional 31,433 shares during the last quarter. Barclays PLC boosted its holdings in Compass Therapeutics by 195.4% in the third quarter. Barclays PLC now owns 170,245 shares of the company’s stock worth $314,000 after acquiring an additional 112,614 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of Compass Therapeutics by 99.7% during the second quarter. Renaissance Technologies LLC now owns 140,600 shares of the company’s stock worth $141,000 after acquiring an additional 70,200 shares during the last quarter. Finally, Rhumbline Advisers increased its holdings in shares of Compass Therapeutics by 10.3% during the second quarter. Rhumbline Advisers now owns 131,789 shares of the company’s stock valued at $132,000 after acquiring an additional 12,315 shares in the last quarter. 68.43% of the stock is owned by hedge funds and other institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.